Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional

BIBTEX RIS

Leishmaniose tegumentar em paciente com espondilite anquilosante utilizando adalimumabe

2012; Elsevier BV; Volume: 52; Issue: 3 Linguagem: Inglês

10.1590/s0482-50042012000300014

1809-4570

Kirla Wagner Poti Gomes, André Nunes Benevides, Francisco José Fernandes Vieira, Maggy Poti de Morais Burlamaqui, Marcos de Almeida e Pontes Vieira, Lysiane Maria Adeodato Ramos Fontenelle,

Autoimmune and Inflammatory Disorders Research

Leishmaniasis is an anthropozoonosis caused by species of Leishmania and can have different clinical presentations, depending on the parasite-host relationship. Tumor necrosis factor-α (TNF-α) is a cytokine essential to infection control, especially against intracellular parasites such as Leishmania. Anti-TNF-α strategies have had a marked impact on the treatment of rheumatic diseases, but the clinical use of those antagonists has been accompanied by an increased report of infections. We report the first case of cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with adalimumab and methotrexate in Brazil. We believe that, in this case, there was no association between the anti-TNF-α treatment and cutaneous leishmaniasis, because the disease was limited to only one ulcer that healed completely after treatment. More studies, however, are necessary to better understand the possible relationship between anti-TNF-α agents and leishmaniasis.